Clinical trials: Hematological Patients
Aspergillosis
Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis
The purpose of this study is to evaluate the therapeutic effectiveness of combination antifungal therapy (CAT) of voriconazole plus micafungin versus voriconazole plus placebo equivalent as primary therapy for invasive…
- Trial name
- NCT01207128
- Testing
- Voriconazole, micafungin
- Where
- 2 sites in United States
- Sponsor
- University of Arkansas
Lymphoma, Leukemia
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
This study evaluated safety, tolerability, pharmacokinetics and preliminary anti-leukemic or anti-tumor activity of LBH589B in adult patients with advanced hematological malignancies
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma
- Trial name
- NCT00621244
- Testing
- LBH589
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Hematological Malignancy
PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM
The aim of this trial is to evaluate the efficacy of GVH prophylaxis reinforced by low-dose Thymoglobulin administered at the end of aplasia after haploidentical allogeneic transplantation.
- Trial name
- CASPER (NCT06066255)
- Testing
- Thymoglobulin Injectable Product
- Volunteers
- 27 people
- Sponsor
- Institut Paoli-Calmettes
Infections, Hematologic Diseases
mNGS Versus Blood Culture in FN
Blood stream infection (BSI) during febrile neutropenia (FN) is a lethal complication, while confirmed diagnosis via blood culture is usually with low sensitivity and time delay.
- Conditions
- Infections, Hematologic Diseases, Febrile Neutropenia
- Trial name
- NCT05149547
- Testing
- blood culture versus mNGS detection
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University People's Hospital
Febrile Neutropenia (FN)
Probability of Optimal Target Attainment of Amikacin in Patients With Febrile Neutropenia During Treatment for a Hematological Disorder
The present trial is a single center, prospective, observational pharmacokinetics and pharmacodynamics (PKPD) cohort study investigating whether patients suffering from a hematological disorder and treated with amikacin due to…
- Trial name
- NCT05689450
- Testing
- Data collection: Amikacin concentration
- Where
- Switzerland
- Volunteers
- 92 people
- Sponsor
- University Hospital, Basel, Switzerland
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00816413
- Testing
- cyclosporine, mycophenolate mofetil, pentostatin
- Sponsor
- University of Nebraska
Hematological Malignancy, Hematopoetic Stem Cell Transplantation
Middle East Study of Infections in Patients With Hematological Malignancies
The goal of this prospective observational study is to is to prospectively study the epidemiology of bloodstream infection (BSI) in patients with hematological malignancies (HM) and hematopoietic stem cell transplant (HSCT)…
- Conditions
- Hematological Malignancy, Hematopoetic Stem Cell Transplantation, Bloodstream Infection
- Trial name
- MESI-HM (NCT07900542)
- Testing
- No Intervention: Observational Cohort
- Where
- 9 sites in Jordan, Oman and 3 more
- Volunteers
- 1,000 people
- Sponsor
- Hamad Medical Corporation
Hematological Malignancies, Critical Illness
Using a Population Pharmacokinetic Model to Estimate the Dosage of Teicoplanin in Patients With Hematologic Malignancy or Critical Illness
Model Informed Precision Dosing (MIPD) integrates clinical data to optimize dosing for patients with unstable pharmacokinetics, like those with hematologic malignancies or critical illnesses.
- Trial name
- NCT06674330
- Testing
- concentration of teicoplanin
- Volunteers
- 600 people
- Sponsor
- National Taiwan University Hospital
AML, NHL
A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS
This is a single-arm, open-label, dose-escalation and dose-expansion phase I clinical trial aimed at assessing the safety, tolerability, pharmacokinetic/pharmacodynamic profile, and preliminary efficacy of FD-001 capsules in the…
- Trial name
- NCT06731699
- Testing
- FD-001
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Chengdu FenDi Pharmaceutical Co., Ltd.
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation
Phase II trial evaluating the safety \& efficacy of Atorvastatin for prophylaxis of Acute Graft Versus Host Disease (GVHD) in patients with hematological malignances undergoing human leukocyte antigen (HLA)-Matched Related Donor…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01491958
- Testing
- atorvastatin, Tacrolimus, methotrexate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome
The Study Seeks to Determine Potential Correlations Between Ventilation and Hematological Alterations, Contributing to a Better Understanding of Its Physiological Effects and Optimizing Patient Management in Critical Care Settings.
The study seeks to determine potential correlations between ventilation and hematological alterations, contributing to a better understanding of its physiological effects and optimizing patient management in critical care…
- Trial name
- NCT07030114
- Testing
- complete blood tests, mechanical ventilation (MV)
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Lymphoma and Acute Lymphoblastic Leukemia
Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies
Development of CAR-T cell against CD19 B lymphoma and Acute Lymphoblastic Leukemia leaded to 2 authorized medication: Yescarta and Kymriah.
- Trial name
- CAR-T BANK (NCT04290000)
- Testing
- additional biological samples during CAR-T CELL treatment
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Montpellier
Transplant-Related Hematologic Malignancy
Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies
Therapeutic exploratory study to evaluate safety, open, nonrandomized, multicentre, prospective, of cohort of patients who will receive different doses of allo-depleted lymphocytes .
- Trial name
- NCT01751243
- Testing
- Allo-depleted lymphocyte infusion, Haploidentical transplantation of hematopoietic progenitors
- Where
- 4 sites in Spain
- Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Aspergillosis
To Determine Whether Galactomannan Test Will Help to Detect Fungal Infections Early and Hence Start Treatment Early
Chemotherapy lowers the white blood cell count or weakens the immune system for a long time. This puts the patients at a high risk of getting a serious fungal infection of the internal organs or blood.
- Trial name
- NCT00361517
- Testing
- Galactomannan antigen monitoring, Aspergillus PCR, blood draws, blood draws for GM monitoring
- Where
- Singapore
- Volunteers
- 47 people
- Sponsor
- Singapore General Hospital
Hematological Malignancies
Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies
The purpose of the study is to determine the safety and tolerability of RGB-286638, a novel, multi-targeted kinase inhibitor, administered to patients with selected, relapsed or refractory hematological malignancies.
- Trial name
- NCT01168882
- Testing
- RGB-286638
- Sponsor
- Agennix
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
RATIONALE: A peripheral stem cell transplant or an umbilical cord blood transplant from a donor may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281879
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- OHSU Knight Cancer Institute
Hematopoietic Recovery
The Safety and Efficacy of Coenzyme I for Injection in Promoting Hematopoietic Recovery of Patients After sUCBT
To assess the safety and efficacy of coenzyme I for injection in promoting hematopoietic recovery after single-unit unrelated cord blood transplantation in hematological malignancies.
- Trial name
- NCT06558253
- Testing
- Coenzyme I for Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Anhui Provincial Hospital
Malignant Mast Cell Tumors, Solid Organ Sites
Evaluation of Patient Satisfaction With and Acceptance of Their Totally-implanted Central Venous Catheter
Background Patient satisfaction with or acceptance of care assessment is increasingly taken into account in oncology. Most cancer and other critically-ill patients require a totally-implanted Central Venous Catheter (CVC) for…
- Trial name
- QASICC-EVA (NCT01616537)
- Testing
- QUALITY OF LIFE QUESTIONNAIRE
- Where
- 10 sites in France
- Volunteers
- 990 people
- Sponsor
- Centre Antoine Lacassagne
Neoplasms, Hematologic Neoplasms
Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 Chimeric Antigen Receptor-T(CAR-T) therapy for patients with CD7-positive relapsed or refractory T-Acute…
- Conditions
- Neoplasms, Hematologic Neoplasms, Neoplasms by Site, Hematologic Diseases
- Trial name
- NCT05895994
- Testing
- RD13-02 cell infusion
- Where
- China
- Volunteers
- 2 people
- Sponsor
- MEI HENG
Hematologic Neoplasms, Thrombocytopenia
Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia
Background: Antithrombotic therapy in the context of treatment related thrombocytopenia (i.e. low levels of platelets) is not uncommon.
- Conditions
- Hematologic Neoplasms, Thrombocytopenia, Anticoagulants, Platelet Aggregation Inhibitors
- Trial name
- MATTER (NCT03288441)
- Testing
- Hold, Prophylactic dose antithrombotic, Change antithrombotic Drug
- Where
- 21 sites in United States, Israel and 2 more
- Volunteers
- 300 people
- Sponsor
- Maastricht University Medical Center